“We are pleased to welcome Dr. Andrews to Catalyst. / … he brings significant experience in biopharmaceuticals to this role,” said Rich Daly, President and CEO, Catalyst. Dr. Andrews brings 24 years of global biopharmaceutical experience across clinical development, medical

Heading to Boston for #BIO2025? Let’s meet. Our Strategy & Business Development Team will be on-site at the BIO International Convention, ready to explore strategic partnerships and opportunities that drive innovation across #biotech and #raredisease. June 16–19 | Boston

We’re headed to Boston for #BIO2025! The BIO International Convention is the perfect backdrop to connect, collaborate, and push innovation forward. Our Strategy & Business Development Team is looking forward to meeting partners passionate about biotech, #raredisease, and bringing

We’re excited to be at the PPMD Annual Conference in Las Vegas #PPMD2025! Visit Team Catalyst’s “Empower Duchenne” booth to connect with our advocacy team and learn how we’re supporting the Duchenne muscular dystrophy (DMD) community. Whether you're a parent, caregiver, or

Team Catalyst is at the PPMD Annual Conference in Las Vegas #PPMD2025! Stop by our “Summit Study” booth to learn about our new research initiatives to help the Duchenne muscular dystrophy (DMD) community. See how you can get involved, together we can make a difference for DMD.

At #PPMD2025? Swing by our #EmpowerDuchenne table! Our team is enjoying connecting, listening to stories/insights, and sharing how we're supporting the DMD community through advocacy, patient services, and an exciting research opportunity. We can't wait to see you! If you're not

"We are an execution machine." We're pleased to announce that our CEO, Rich Daly, was a recent guest on BioSpace's "Denatured" podcast. During the discussion, he provided crucial insights into the present funding environment, incorporating perspectives from #BIO2025 and

#Happy4thOfJuly

We’re proud to sponsor the 2025 What Now Conference, hosted by Team Joseph , a unique event created by and for young adults living with Duchenne muscular dystrophy July 16-17th. This powerful day of connection, learning, and community was designed by a planning committee of

Are you at PER's 26th Annual International Lung Cancer Congress #ILCC2025? Visit Catalyst's booth to learn about the link between small cell lung cancer (SCLC) and Lambert-Eaton myasthenic syndrome, a progressive neurologic paraneoplastic syndrome that significantly impacts

Our Chief Strategy Officer, Preethi Sundaram, shared with PharmaVoice her insights on Catalyst's role in the evolving drug development landscape and how the company can play a part. “It’s a chance to push the bar and grab things that are sufficiently derisked from companies that

Healthcare providers, today marks World Lung Cancer Day. 50%-60% of Lambert-Eaton myasthenic syndrome (LEMS) patients have a co-occurring cancer. In Cancer-Associated LEMS, small cell lung cancer (SCLC) is the most common. Learn how to confirm a LEMS diagnosis in new patients:

“Early diagnosis of LEMS in SCLC is critical, as it may enable patients to have better outcomes if their LEMS symptoms are effectively treated while fighting SCLC. Accurate identification through VGCC antibody testing and comprehensive neurological evaluation is essential,” said

Strong performance, strategic execution, and continued momentum — Catalyst Pharmaceuticals reports record Q2 and first half 2025 financial results. Our results reflect another consecutive quarter of growth, underscoring the strength of our commercial strategy and long-term value

Catalyst proudly welcomes Dr. Daniel Curran to our Board of Directors. “Dan brings an exceptional combination of strategic insight, rare disease expertise, and business development acumen, making him an outstanding addition to our Board.” - Patrick McEnany, Chairman of the

We’re honored to share that Catalyst has been nominated for the Prix Galien Award in the Best Biotechnology Product category. This recognition underscores our commitment to advancing innovative therapies for those living with rare diseases. View the full list of nominees:

The Health Resources and Services Administration (HRSA), an agency of the Federal government, is considering adding Duchenne Muscular Dystrophy (DMD) to the Recommended Uniform Screening Panel (RUSP) for newborns. This addition to the RUSP would mean that non-grandfathered health

To help ease the challenges of people living with a rare disease, we created Catalyst Pathways. This free program is dedicated to providing personalized support and assistance for patients and their families who are on our treatments, like AGAMREE. We shared details with

On #CatalystConvos, we explore the unique challenges of reaching rare disease patients in rural areas—and how trust is the first step with Terri Klein, President & CEO of the the MPS Society. Listen now: brnw.ch/21wV1NT

Catalyst Pharmaceuticals is excited to partner with CureDuchenne on a free workshop in Costa Mesa, CA on August 23. This workshop is aimed at informing and connecting individuals with Duchenne muscular dystrophy (DMD) and their families with resources that will improve their